Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | The current treatment landscape for SCD

Robert Clark Brown, MD, PhD, Children’s Healthcare of Atlanta, Atlanta, GA, gives an overview of the current treatment landscape for sickle cell disease (SCD), highlighting the use of hydroxyurea and the use of more recently approved therapies including voxelotor, L-glutamine and crizanlizumab. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.


Robert Clark Brown, MD, PhD, has participated in consultancy work with Global Blood Therapeutics, Imara and Novo Nordisk; and has received research support from Forma Therapeutics, Global Blood Therapeutics, Imara and Novartis.